OIPE
APR 02 2004
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/678,346
Filing Date	October 3, 2003
First Named Inventor	Daniel Castro
Group Art Unit	1615
Examiner Name	Unassigned
Total Number of Pages in This Submission (excluding references) 16	**Attorney Docket No.** 50623.344

ENCLOSURES *(check all that apply)*

- ☒ Deposit Account Authorization 07-1850
- ☒ Postage Paid Return Postcard
- ☐ Response to Office Action
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Petition for Extension of Time (__ month) (in duplicate)
- ☐ Amendment Transmittal Letter (in duplicate)
- ☒ Information Disclosure Statement with Form PTO-1449 citing 291 References
- ☐ Request for Continued Examination (RCE) Transmittal
- ☐ Express Mail Label No.
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Formal Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) ____
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Submission of Formal Drawings (in duplicate)
- ☒ Other Enclosure(s) *(please identify below)*:
  - **48 Foreign Patent Documents**
  - **45 Other Non-Patent Documents**
  - **1 Unpublished Patent Application**

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm *or* Individual name	Squire, Sanders & Dempsey L.L.P. Paul J. Meyer, Jr., Reg. No. 47,791
Signature	
Date	March 31, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name	Dilora Haddad		
Signature		Date	March 31, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

OIPE
APR 0 2 2004
JC53
PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Daniel Castro et al.	Examiner:	Unassigned
Serial No.	10/678,346	Art Unit:	1615
Filed:	October 3, 2003		
Title:	Barriers for Polymer-Coated Implantable Medical Devices and Methods for Making the Same		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicants have not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited unpublished patent application, foreign patent documents and non-patent literature have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: March 31, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,

Paul J. Meyer, Jr.
Attorney for Applicants
Reg. No. 47,791

OIPE
APR 0 2 2004
JC53
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (Modified) US DEPARTMENT OF COMMERCE
Approved for use through 10/31/2002 US Patent and Trademark Office

INFORMATION DISCLOSURE CITATION in an Application

(Use several sheets if necessary)

Docket No.	Application No.
50623.344	10/678,346
Applicant: Daniel Castro et al.	
Filing Date: October 3, 2003	Group Art Unit: 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,329,383	5/11/82	Joh	428	36	
	A2	4,733,665	3/29/88	Palmaz	128	343	
	A3	4,800,882	1/31/89	Gianturco	128	343	
	A4	4,882,168	11/21/89	Casey et al.	424	468	
	A5	4,886,062	12/12/89	Wiktor	128	343	
	A6	4,941,870	7/17/90	Okada et al.	600	36	
	A7	4,977,901	12/18/90	Ofstead	128	772	
	A8	5,064,435	11/12/91	Porter	623	12	
	A9	5,071,407	12/10/91	Termin et al.	604	104	
	A10	5,078,736	1/7/92	Behl	623	1	
	A11	5,092,841	3/3/92	Spears	604	96	
	A12	5,112,457	5/12/92	Marchant	204	165	
	A13	5,165,919	11/24/92	Sasaki et al.	424	488	
	A14	5,272,012	12/21/93	Opolski	428	423.1	
	A15	5,292,516	3/8/94	Viegas et al.	424	423	
	A16	5,298,260	3/29/94	Viegas et al.	424	486	
	A17	5,300,295	4/5/94	Viegas et al.	424	427	
	A18	5,306,501	4/26/94	Viegas et al.	424	423	
	A19	5,328,471	7/12/94	Slepian	604	101	
	A20	5,330,768	7/19/94	Park et al.	424	501	
	A21	5,344,411	9/6/94	Domb et al.	604	265	
	A22	5,344,425	9/6/94	Sawyer	606	198	
	A23	5,380,299	1/10/95	Fearnot et al.	604	265	
	A24	5,417,981	5/23/95	Endo et al.	424	486	
	A25	5,447,724	9/5/95	Helmus et al.	424	426	
	A26	5,455,040	10/3/95	Marchant	424	426	

	A27	5,462,990	10/31/95	Hubbell et al.	525	54.1	
	A28	5,464,650	11/7/95	Berg et al.	427	2.30	
	A29	5,474,089	12/12/95	Waynant	128	843	
	A30	5,569,463	10/29/96	Helmus et al.	424	426	
	A31	5,571,086	11/5/96	Kaplan et al.	604	96	
	A32	5,576,072	11/19/96	Hostettler et al.	427	532	
	A33	5,578,073	11/26/96	Haimovich et al.	623	1	
	A34	5,605,696	2/25/97	Eury et al.	424	423	
	A35	5,609,629	3/11/97	Fearnot et al.	623	1	
	A36	5,624,411	4/29/97	Tuch	604	265	
	A37	5,628,730	5/13/97	Shapland et al.	604	21	
	A38	5,628,730	5/13/97	Shapland et al.	604	21	
	A39	5,649,977	7/22/97	Campbell	623	1	
	A40	5,658,995	8/19/97	Kohn et al.	525	432	
	A41	5,662,960	9/2/97	Hostettler et al.	427	2.3	
	A42	5,667,767	9/16/97	Greff et al.	424	9.411	
	A43	5,670,558	9/23/97	Onishi et al.	523	112	
	A44	5,676,685	10/14/97	Razavi	606	194	
	A45	5,679,400	10/21/97	Tuch	427	2.14	
	A46	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A47	5,702,754	12/30/97	Zhong	427	2.12	
	A48	5,716,981	2/10/98	Hunter et al.	514	449	
	A49	5,728,152	3/17/98	Mirsch, II et al.	623	2	
	A50	5,735,897	4/7/98	Buirge	623	12	
	A51	5,746,998	5/5/98	Torchilin et al.	424	9.4	
	A52	5,762,638	6/9/98	Shikani et al.	604	265	
	A53	5,776,184	7/7/98	Tuch	623	1	
	A54	5,788,979	8/4/98	Alt et al.	424	426	
	A55	5,792,550	8/11/98	Phillips et al.	428	336	
	A56	5,800,392	9/1/98	Racchini	604	96	
	A57	5,820,917	10/13/98	Tuch	427	2.1	
	A58	5,824,048	10/20/98	Tuch	623	1	

	A59	5,824,049	10/20/98	Ragheb et al.	623	1	
	A60	5,830,178	11/3/98	Jones et al.	604	49	
	A61	5,830,430	11/3/98	Unger et al.	424	1.21	
	A62	5,837,008	11/17/98	Berg et al.	623	1	
	A63	5,837,313	11/17/98	Ding et al.	427	2.21	
	A64	5,843,156	12/1/98	Slepian et al.	623	1	
	A65	5,849,035	12/15/98	Pathak et al.	623	1	
	A66	5,849,368	12/15/98	Hostettler et al.	427	536	
	A67	5,851,508	12/22/98	Greff et al.	424	9.411	
	A68	5,854,382	12/29/98	Loomis	528	354	
	A69	5,855,563	1/5/99	Kaplan et al.	604	49	
	A70	5,855,599	1/5/99	Wan	623	1	
	A71	5,858,746	1/12/99	Hubbell et al.	435	177	
	A72	5,858,990	1/12/99	Walsh	514	44	
	A73	5,865,814	2/2/99	Tuch	604	265	
	A74	5,869,127	2/9/99	Zhong	427	2.12	
	A75	5,873,904	2/23/99	Ragheb et al.	623	1	
	A76	5,876,433	3/2/99	Lunn	623	1	
	A77	5,877,224	3/2/99	Brocchini et al.	514	772.2	
	A78	5,895,420	4/20/99	Mirsch, II et al.	623	2	
	A79	5,898,066	4/27/99	Benowitz et al.	530	300	
	A80	5,899,935	5/4/99	Ding	623	1	
	A81	5,911,702	6/15/99	Romley et al.	604	53	
	A82	5,919,570	7/6/99	Hostettler et al.	428	424.8	
	A83	5,925,720	7/20/99	Kataoka et al.	525	523	
	A84	5,951,458	9/14/99	Hastings et al.	600	3	
	A85	5,955,509	9/21/99	Webber et al.	514	772.7	
	A86	5,961,547	10/5/99	Razavi	623	1	10/14/97
	A87	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
	A88	5,980,928	11/9/99	Terry	424	427	7/29/97
	A89	5,980,972	11/9/99	Ding	427	2.24	9/22/97
	A90	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
	A91	6,005,020	12/21/99	Loomis	523	105	9/2/98

	A92	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A93	6,013,780	1/11/00	Neufeld et al.	536	23.1	1/21/97
	A94	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A95	6,017,577	1/25/00	Hostettler et al.	427	2.12	2/1/95
	A96	6,022,901	2/8/00	Goodman	514	733	5/13/98
	A97	6,026,316	2/15/00	Kucharczyk et al.	600	420	5/15/97
	A98	6,028,164	2/22/00	Loomis	528	354	2/1/99
	A99	6,030,656	2/29/00	Hostettler et al.	427	2.3	3/24/98
	A100	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A101	6,040,058	3/21/00	Hostettler et al.	428	457	8/27/98
	A102	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
	A103	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A104	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A105	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A106	6,056,938	5/2/00	Unger et al.	424	1.21	5/5/98
	A107	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A108	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A109	6,061,587	5/9/00	Kucharczyk et al.	600	411	5/15/97
	A110	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A111	6,086,773	7/11/00	Dufresne et al.	216	8	5/22/98
	A112	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A113	6,096,726	8/1/00	Opolski	514	53	3/11/98
	A114	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A115	6,102,046	8/15/00	Weinstein et al.	128	898	6/2/98
	A116	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A117	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A118	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A119	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A120	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A121	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A122	6,126,649	10/3/00	VanTassel et al.	604	528	6/10/99
	A123	6,129,761	10/10/00	Hubbell	623	11	6/7/95
	A124	6,136,006	10/24/00	Johnson et al.	606	108	7/27/98

	A125	6,140,452	10/31/00	Felt et al.	528	60	11/18/98
	A126	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A127	6,156,064	12/5/00	Chouinard	623	1.44	8/14/98
	A128	6,156,350	12/5/00	Constantz	424	666	12/2/99
	A129	6,159,232	12/12/00	Nowakowski	606	213	12/15/98
	A130	6,162,244	12/19/00	Braun et al.	623	1.12	9/23/98
	A131	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	A132	6,178,346	1/23/01	Amundson et al.	600	473	10/23/98
	A133	6,179,817	1/30/01	Zhong	604	265	1/28/99
	A134	6,183,469	2/6/01	Thapliyal et al.	606	41	1/2/98
	A135	6,197,051	3/6/01	Zhong	623	1.46	2/11/99
	A136	6,203,551	3/20/01	Wu	606	108	10/4/99
	A137	6,211,247	4/3/01	Goodman	514	733	11/4/99
	A138	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A139	6,238,364	5/29/01	Becker	604	8	2/9/00
	A140	6,240,616	6/5/01	Yan	29	527.2	4/15/97
	A141	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	A142	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
	A143	6,249,952	6/26/01	Ding	29	460	3/8/99
	A144	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A145	6,254,634	7/3/01	Anderson et al.	623	1.42	6/10/98
	A146	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	A147	6,261,320	7/17/01	Tam et al.	623	1.15	2/19/99
	A148	6,265,016	7/24/01	Hostettler et al.	427	2.11	3/21/00
	A149	6,265,199	7/24/01	Sheppard et al.	435	212	7/9/99
	A150	6,274,164	8/14/01	Novich	424	443	9/15/00
	A151	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
	A152	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
	A153	6,283,951	9/4/01	Flaherty et al.	604	529	3/25/98
	A154	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	A155	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99

	A156	6,287,249	9/11/01	Tam et al.	600	3	2/19/99
	A157	6,290,729	9/18/01	Slepian et al.	623	23.72	12/3/97
	A158	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	A159	6,302,875	10/16/01	Makower et al.	604	528	4/11/97
	A160	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
	A161	6,306,177	10/23/01	Felt et al.	623	23.6	12/18/97
	A162	6,316,522	11/13/01	Loomis et al.	523	105	9/14/99
	A163	6,322,771	11/27/01	Linden et al.	424	9.3	6/18/99
	A164	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
	A165	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
	A166	6,334,867	1/1/02	Anson	623	1.13	3/6/98
	A167	6,346,110	2/12/02	Wu	606	108	1/3/01
	A168	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
	A169	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A170	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
	A171	6,391,052	5/02	Buirge	204	499	10/29/97
	A172	6,410,044	6/02	Chudzik	424	423	5/16/00
	A173	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
	A174	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
	A175	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A176	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
	A177	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
	A178	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
	A179	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A180	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A181	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A182	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A183	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A184	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
	A185	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00

	A186	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
	A187	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
	A188	6,572,644	6/3/03	Moein	623	1.11	6/27/01
	A189	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
	A190	6,585,926	7/1/03	Mirzaee	264	400	8/31/00
	A191	6,605,154	8/12/03	Villareal	118	500	5/31/01
	A192	09/750,595		Hossainy et al.			12/28/00

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
	A193	2001/0018469	8/30/01	Chen et al.	523	121	12/28/00
	A194	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21/01
	A195	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/19/00
	A196	2002/0091433	7/11/02	Ding et al.	623	1.2	12/17/01
	A197	2002/0155212	10/24/02	Hossainy	427	2.25	4/24/01
	A198	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30/02
	A199	2003/0099712	5/29/03	Jayaraman	424	486	11/26/01

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 0 301 856	2/1/89	European				
	B2	EP 0 514 406	11/25/92	European				
	B3	EP 0 604 022	6/29/94	European				
	B4	EP 0 623 354	11/9/94	European				
	B5	EP 0 665 023	8/2/95	European				
	B6	EP 0 701 802	3/20/96	European				
	B7	EP 0 716 836	6/19/96	European				
	B8	EP 0 809 999	12/3/97	European				
	B9	EP 0 832 655	4/1/98	European				
	B10	EP 0 850 651	7/1/98	European				
	B11	EP 0 879 595	11/25/98	European				
	B12	EP 0 910 584	4/28/99	European				
	B13	EP 0 923 953	6/23/99	European				
	B14	EP 0 953 320	11/3/99	European				

	B15	EP 0 970 711	1/12/00	European				
	B16	EP 0 982 041	3/1/00	European				
	B17	EP 1 273 314	1/8/03	European				
	B18	2001-190687	7/17/01	Japan (Abstract)			X	
	B19	WO 91/12846	9/5/91	PCT				
	B20	WO 95/10989	4/27/95	PCT				
	B21	WO 96/40174	12/19/96	PCT				
	B22	WO 97/10011	3/20/97	PCT				
	B23	WO 97/45105	12/4/97	PCT				
	B24	WO 97/46590	12/11/97	PCT				
	B25	WO 98/17331	4/30/98	PCT				
	B26	WO 98/36784	8/27/98	PCT				
	B27	WO 99/01118	1/14/99	PCT				
	B28	WO 99/38546	8/5/99	PCT				
	B29	WO 99/63981	12/16/99	PCT				
	B30	WO 00/02599	1/20/00	PCT				
	B31	WO 00/12147	3/9/00	PCT				
	B32	WO 00/18446	4/6/00	PCT				
	B33	WO 00/64506	11/2/00	PCT				
	B34	WO 01/01890	1/11/01	PCT				
	B35	WO 01/15751	3/8/01	PCT				
	B36	WO 01/17577	3/15/01	PCT				
	B37	WO 01/45763	6/28/01	PCT				
	B38	WO 01/49338	7/12/01	PCT				
	B39	WO 01/74414	10/11/01	PCT				
	B40	WO 02/03890	1/17/02	PCT				
	B41	WO 02/026162	4/4/02	PCT				
	B42	WO 02/34311	5/2/02	PCT				
	B43	WO 02/056790	7/25/02	PCT				
	B44	WO 03/000308	1/3/03	PCT				
	B45	WO 03/022323	3/20/03	PCT				

	B46	WO 03/028780	4/10/03	PCT				
	B47	WO 03/037223	5/8/03	PCT				
	B48	WO 03/039612	5/15/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Anonymous, *Cardiologists Draw - Up The Dream Stent*, Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959, printed 8/25/03 (2 pages).
	C2	Anonymous, *Heparin-coated stents cut complications by 30%*, Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753, printed 8/25/03 (2 pages).
	C3	Anonymous, *Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent* (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).
	C4	Anonymous, *Stenting continues to dominate cardiology*, Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?req=1061848017752, printed 8/25/03 (2 pages).
	C5	Aoyagi et al., *Preparation of cross-linked aliphatic polyester and application to thermo-responsive material*, Journal of Controlled Release 32:87-96 (1994).
	C6	Atotech, *Pallatect™ A Process For Autocatalytic Deposition of Palladium*, http://www.insulectro.com/Pallatect.pdf , printed March 17, 2004 (4 pages).
	C7	Atotech, *Atotech Global-Home*, http://www.atotech.com/start.php3?cl_my_id=30574, printed March 17, 2004 (1 page).
	C8	Barath et al., *Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury*, JACC 13(2): 252A (Abstract) (Feb. 1989).
	C9	Barbucci et al., *Coating of commercially available materials with a new heparinizable material*, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).
	C10	Baudrand et al., *Electroless Palladium, Past and Future*, Proceedings of the AESF annual technical conference American Electroplaters and Surface Finishers Society, 1999, pp. 49-51.
	C11	Chemical Business Newsbase, "*Headline: Modern Plastics International: New PET barrier technologies show promise in beer bottles*", Copyright 2000 FT Asia Intelligence Wire, March 10, 2000 (1 page).
	C12	Chung et al., *Inner core segment design for drug delivery control of thermo-responsive polymeric micelles*, Journal of Controlled Release 65:93-103 (2000).
	C13	Dev et al., *Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs*, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
	C14	Dichek et al., *Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells*, Circ. 80(5):1347-1353 (Nov. 1989).
	C15	DNP Products & Services – Packaging, "Barrier Carton for Liquid L-Carton L-Barrier L-Alumi," http://www.dnp.co.jp/international/pack/carton/carton_1.html, printed March 17, 2004 (1 page).
	C16	DNP Products & Services – Packaging, "Barrier Carton for Liquid L-Carton L-Barrier L-Alumi," http://www.dnp.co.jp/international/pack/carton/carton_2.html, printed March 17, 2004 (2 pages).
	C17	DNP Products & Services – Packaging, "Barrier Carton for Liquid L-Carton L-Barrier L-Alumi," http://www.dnp.co.jp/international/pack/carton/carton_3.html, printed March 17, 2004 (1 page).
	C18	Eigler et al., *Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin*, JACC, 4A (701-1), Abstract (Feb. 1994).
	C19	Electro-Coatings of Iowa, Inc., "Kanigen® Electroless Nickel Alloy," http://www.platingforindustry.com/electrocoatings/kantech.htm, printed March 17, 2004 (3 pages).
	C20	Erlat et al., *Morphology And Gas Barrier Properties Of Thin SiO_x Coatings On Polycarbonate: Correlations With Plasma-Enhanced Chemical Vapor Deposition Conditions*, J. Mater. Res., Vol. 15, No. 3, Mar. 2000, pp. 704-717.
	C21	Helmus, *Overview of Biomedical Materials*, MRS Bulletin, pp. 33-38 (Sept. 1991).

	C22	Herdeg et al., *Antiproliferative Stent Coatings: Taxol and Related Compounds*, Semin. Intervent. Cardiol. 3:197-199 (1998).
	C23	Inoue et al., *An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs*, Journal of Controlled Release 51:221-229 (1998).
	C24	Kataoka et al., *Block copolymer micelles as vehicles for drug delivery*, Journal of Controlled Release 24:119-132 (1993).
	C25	Levy et al., *Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants*, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
	C26	Liu et al., *Drug release characteristics of unimolecular polymeric micelles*, Journal of Controlled Release 68:167-174 (2000).
	C27	Marconi et al., *Covalent bonding of heparin to a vinyl copolymer for biomedical applications*, Biomaterials 18(12):885-890 (1997).
	C28	Matsumaru et al., *Embolic Materials For Endovascular Treatment of Cerebral Lesions*, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C29	Mitsubishi Chemical Kohjin PAX Corporation, "Transparent Excellent Gas Barrier Plastic Film ... TECHBARRIER®," http://www.techbarrier.com/techbarrier/index.htm, printed March 17, 2004 (3 pages).
	C30	Mitsubishi Chemical Kohjin PAX Corporation, "TECHBARRIER®-S," http://www.techbarrier.com/techbarrier/tech-s.htm, printed March 17, 2004 (2 pages).
	C31	Mitsubishi Chemical Kohjin PAX Corporation, "How to Handle and Convert TECHBARRIER®," http://www.techbarrier.com/techbarrier/tech-kakou.htm, printed March 17, 2004 (2 pages).
	C32	Miyazaki et al., *Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice*, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C33	Miyazawa et al., *Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat*, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C34	Modern Plastics, *New PET Barrier Technologies Show Promise in Beer Bottle Advances to be on Tap At Industry Event*, http://www.modplas.com/news/month_0100/gr01.htm, printed December 3, 2002 (6 pages).
	C35	Nordrehaug et al., *A novel biocompatible coating applied to coronary stents*, European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C36	Ohsawa et al., *Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty*, American Heart Journal 136(6):1081-1087 (Dec. 1998).
	C37	Ozaki et al., *New Stent Technologies*, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C38	Pharmaceutical & Medical Packaging News, "Film Preserves Blood Substitute," http://www.devicelink.com/grabber.php3?URL=http:www.devicelink.com/pmpn/achive, printed December 10, 2003 (3 pages).
	C39	Pechar et al., *Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin*, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	C40	Peng et al., *Role of polymers in improving the results of stenting in coronary arteries*, Biomaterials 17:685-694 (1996).
	C41	Shigeno, *Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor*, Chemical Abstract 125:212307 (1996).
	C42	van Beusekom et al., *Coronary stent coatings*, Coronary Artery Disease 5(7):590-596 (July 1994).
	C43	Wilensky et al., *Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries*, Trends Cardiovasc. Med. 3(5):163-170 (1993).

	C44	Yokoyama et al., *Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor*, Journal of Controlled Release 50:79-92 (1998).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.